![]() |
|
|
Vol. 296, Issue 3, 980-986, March 2001
Department of Physiology and Pharmacology, College of Veterinary
Medicine, The University of Georgia, Athens, Georgia
Previously we reported that SNAP-25, synaptobrevin II, and syntaxin I,
the intracellular substrates of botulinum toxin originally identified
in nontarget tissues, were present in a recognized mammalian target
tissue, the mouse hemidiaphragm. Furthermore, we reported that SNAP-25,
syntaxin I, and synaptobrevin II were cleaved by incubation of the
intact hemidiaphragm in botulinum serotypes A, C, and D, respectively.
The objective of the current study was to use the mouse phrenic
nerve-hemidiaphragm preparation and botulinum serotype A to investigate
1) the relationship of substrate cleavage to toxin-induced paralysis,
and 2) the relevance of substrate cleavage to the mechanism of toxin
action. Immunoblot examination of tissues paralyzed by botulinum toxin
type A (10
8 M) revealed
10% loss of SNAP-25
immunoreactivity at 1 h postparalysis, and
75% loss at 5 h
postparalysis. Triticum vulgaris lectin, an agent that
competitively antagonizes toxin binding, antagonized toxin-induced
paralysis as well as SNAP-25 cleavage. Methylamine hydrochloride, an
agent that prevents pH-dependent translocation, also antagonized
toxin-induced paralysis and SNAP-25 cleavage. Furthermore, zinc
chelation antagonized toxin-induced paralysis and SNAP-25 cleavage.
These results demonstrate that cleavage of SNAP-25 by botulinum
serotype A fulfills the requirements of the multistep model of
botulinum toxin action that includes receptor-mediated endocytosis,
pH-dependent translocation, and zinc-dependent proteolysis. Furthermore, the minimal amount of SNAP-25 cleavage at 1 h
postparalysis suggests that inactivation of only a small but
functionally important pool of SNAP-25 is necessary for paralysis.
This article has been cited by other articles:
![]() |
J. A. Coffield and X. Yan Neuritogenic Actions of Botulinum Neurotoxin A on Cultured Motor Neurons J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 352 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cai, C. B. Adrion, and J. E. Keller Comparison of extracellular and intracellular potency of botulinum neurotoxins. Infect. Immun., October 1, 2006; 74(10): 5617 - 5624. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Morris, P. Jobling, and I. L. Gibbins Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2627 - H2635. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Morris, P. Jobling, and I. L. Gibbins Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H2124 - H2132. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kalandakanond and J. A. Coffield Cleavage of Intracellular Substrates of Botulinum Toxins A, C, and D in a Mammalian Target Tissue J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 749 - 755. [Abstract] [Full Text] |
||||